STROMABLAST Trademark
Trademark Overview
On Tuesday, February 18, 2025, a trademark application was filed for STROMABLAST with the United States Patent and Trademark Office. The USPTO has given the STROMABLAST trademark a serial number of 99045443. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Tuesday, April 7, 2026. This trademark is owned by Simcere Zaiming, Inc.. The STROMABLAST trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
Research on the subject of pharmaceuticals; Pharmaceutical research services; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and biotechnology fields; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Research and development of pharmaceutical preparations for treating malignant tumours; Research and development services in the field of pharmaceutical preparations; Research and development services of new pharmaceutical products; Scientific research in the field of pharmaceuticals and biotechnology; Medical and scientific research in the field of cancer treatment and diagnosis; Biotechnology research; Scientific research for medical purposes in the area of cancerous diseases; Biological research; ...
General Information
| Serial Number | 99045443 |
| Word Mark | STROMABLAST |
| Filing Date | Tuesday, February 18, 2025 |
| Status | 748 - STATEMENT OF USE - TO EXAMINER |
| Status Date | Tuesday, April 7, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 26, 2025 |
Trademark Statements
| Pseudo Mark | STROMA BLAST |
| Goods and Services | Research on the subject of pharmaceuticals; Pharmaceutical research services; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development in the pharmaceutical and biotechnology fields; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Research and development of pharmaceutical preparations for treating malignant tumours; Research and development services in the field of pharmaceutical preparations; Research and development services of new pharmaceutical products; Scientific research in the field of pharmaceuticals and biotechnology; Medical and scientific research in the field of cancer treatment and diagnosis; Biotechnology research; Scientific research for medical purposes in the area of cancerous diseases; Biological research; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Providing laboratory research services in the field of gene expression, namely, cancer biology; Biomedical research services; Research and development of vaccines and medicines; Laboratory research services relating to pharmaceuticals; Research and development services in the field of antibodies; Medical research in the field of oncology; Scientific research in the field of genetics and genetic engineering; Medical research services in the field of cancer; Drug screening for scientific research purposes; Research in the field of bioengineering; Research in the field of synthetic biology; Cell culture services for scientific and research purposes, for others; Research in the field of plant genetic engineering technology; Research and development of siRNA drugs; Medical research laboratory services in the field of oncology; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Biochemical research and development services; Research and development services in the field of biotechnology; Research and development services relating to medicines; Research and development of medicines; Research and development services in the field of medical preparations; Research in the field of bioinformatics; Research in the field of immunodeficiency |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, February 18, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | Thursday, October 31, 2024 |
| First Use In Commerce Date | Monday, December 16, 2024 |
Trademark Owner History
| Party Name | Simcere Zaiming, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02140
US |
| Party Name | Simcere Zaiming, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Cambridge, MA 02140
US |
Trademark Events
| Event Date | Event Description |
| Tuesday, February 18, 2025 | NEW APPLICATION ENTERED |
| Tuesday, February 18, 2025 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, July 15, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, July 24, 2025 | ASSIGNED TO EXAMINER |
| Thursday, July 24, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, August 20, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, August 26, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, August 26, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 21, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Saturday, October 25, 2025 | TEAS STATEMENT OF USE RECEIVED |
| Saturday, October 25, 2025 | USE AMENDMENT FILED |
| Tuesday, April 7, 2026 | STATEMENT OF USE PROCESSING COMPLETE |
